Expression of Inflammatory Proteins in Pancreatic Cancer

NCT ID: NCT00551057

Last Updated: 2010-09-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-10-31

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to investigate the expression of different inflammatory proteins in cancer and normal pancreatic tissue.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Purpose: to investigate the expression of different inflammatory proteins in cancer and normal pancreatic tissue

* Trial with surgical intervention

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Expression type

to investigate the expression of different inflammatory proteins in cancer and normal pancreatic tissue

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with pancreatic cancer or chronic pancreatitis

Exclusion Criteria

* Patients with alpha 1-antitrypsin deficiency
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University Hospital Zurich/VIS Klinik f. Viszeralchirurgie

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marc Schiesser, MD

Role: PRINCIPAL_INVESTIGATOR

UniversitaetsSpital Zuerich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Zurich Department of Surgery

Zurich, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marc Schiesser, MD

Role: CONTACT

+41 (0)44 255 11 11

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marc Schiesser

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

13-2007

Identifier Type: -

Identifier Source: org_study_id